Navigation Links
Penwest Pharmaceuticals Announces Intention to Terminate NASDAQ Listing and Registration
Date:10/15/2010

PATTERSON, N.Y., Oct. 15 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals (Nasdaq: PPCO) ("Penwest") today announces its intention to strike the shares of its common stock from listing and registration on The NASDAQ Stock Market ("NASDAQ"). Penwest intends to take this action in connection with the anticipated merger (the "Merger") of West Acquisition Corp. ("Merger Sub"), an indirect wholly-owned subsidiary of Endo Pharmaceuticals Holdings Inc. ("Endo") (Nasdaq: ENDP), with and into Penwest pursuant to the Agreement and Plan of Merger among Penwest, Merger Sub and Endo, dated August 9, 2010. As previously announced, a special meeting of Penwest shareholders will be held on November 4, 2010 to approve the Merger. Endo and its affiliates own approximately 90.56% of Penwest common stock, and their shares represent sufficient votes to approve the Merger. Penwest intends to consummate the Merger as soon as possible following shareholder approval pursuant to applicable law. Following the completion of the Merger, shares of Penwest common stock will no longer be listed or registered on NASDAQ, or any other stock exchange or quotation system, and upon application to the SEC will be deregistered under the Exchange Act of 1934. Following the completion of the Merger, Penwest will no longer be a public company.

About Penwest

Penwest is a drug development company focused on identifying and developing products that address unmet medical needs, primarily for rare disorders of the nervous system. We are currently developing A0001, or a-tocopherolquinone, a coenzyme Q analog, for inherited mitochondrial respiratory chain diseases. We are also applying our drug delivery technologies and drug formulation expertise to the formulation of product candidates under licensing collaborations. www.penwest.com.


'/>"/>
SOURCE Penwest Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals
2. ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2010 Financial Results
3. Isis Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
5. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
6. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
7. Prolong Pharmaceuticals Secures $30 Million in Funding
8. Amylin Pharmaceuticals to Webcast Third Quarter Results
9. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
10. Titan Pharmaceuticals Announces Journal of the American Medical Association Publication of Phase 3 Probuphine™ Data
11. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... been named one of Michigan’s 2017 Best and Brightest in Wellness® by Best ... in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief ... advancements to physician colleagues, skilled nursing facility medical directors and other clinicians at ... of Wound Care." , "At many of these conferences we get to educate ...
Breaking Medicine News(10 mins):